Project Grant R03CA313537
Award Date 6/8/26
Completion Date 5/30/28
Dollars Obligated $151K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Austin, TX 78712, USA
Similar Awards
- Federal Project Grant Award Summary The University of Texas at Austin received a $668,878 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on April 3, 2026, with completion scheduled for March 31, 2031. This award funds the development of a novel antibody-drug conjugate (ADC)-based therapeutic platform targeting CD44 variant 9 (CD44V9) to treat aggressive and treatment-resistant breast cancer, particularly triple-negative and...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Texas at Austin a $2.59 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. The award supports research to develop a novel cancer immunotherapy approach targeting immune-excluded or "cold" tumors that typically demonstrate poor response to immune checkpoint therapy. The project focuses on demonstrating that degradation of...
- Federal Grant Award Summary The National Cancer Institute awarded a $396,377 Project Grant to the University of Texas at Austin on May 7, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize mutational signatures at hotspots of genetic instability in human cancer genomes. The research project, with a completion date of April 30, 2028, integrates large-scale cancer genome analyses, gene perturbation experiments, and environmental mutagen exposure data to...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $639,514 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026, through May 31, 2031. This five-year research initiative focuses on mechanistic characterization of benzothiazepinone inhibition of NVL (Norovirus-Like), an essential AAA+ adenosine triphosphatase (ATPase) enzyme involved in ribosomal large subunit (60S)...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $370,173 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded September 9, 2025, with a completion date of August 31, 2030. This project delivers research and development of advanced genetic interaction measurement and characterization methodologies for cancer cells, with a primary focus on synthetic lethality as a...
- Federal Project Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded a $164,000 Project Grant to The University of Texas MD Anderson Cancer Center, effective September 1, 2025, through August 31, 2027. This award supports research investigating the clonal determinants of platinum/PARP inhibitor (PARPi) cross-resistance in high-grade serous ovarian cancer (HGSOC). The research utilizes a novel somatic mosaic genetically-engineered mouse model...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $402,011 Project Grant to The University of Texas Southwestern Medical Center under the Cancer Biology Research program (CFDA 93.396) for the period May 1, 2026 through April 30, 2031. This five-year research project investigates the molecular mechanisms by which the KEAP1-NRF2 (Kelch-like ECH-associated protein 1–Nuclear factor erythroid 2-related factor 2) redox-sensing pathway regulates CD8 T cell adaptation to...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $421,685 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The University of Texas MD Anderson Cancer Center, effective August 1, 2025, through July 31, 2027. This award supports pan-cancer analysis of convergent immunoglobulins from tumor-infiltrating B cells (TIL-B), with the primary deliverable being the identification and characterization of shared B cell receptors (BCR) and antibodies across...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $688,073 to The University of Texas MD Anderson Cancer Center on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to support a five-year project through May 31, 2031. Under the direction of Principal Investigator Dr. Peter Van Loo, this project will develop novel computational approaches to reconstruct the evolutionary history of cancer metastases. The research leverages DNA sequencing and molecular...